Emerging targeted therapies for bladder cancer: A disease waiting for a drug

Simon J. Dovedi, Barry R. Davies

    Research output: Contribution to journalArticlepeer-review


    Urothelial cell carcinoma is the fifth most common cancer and the costliest to treat. This is largely because of all new cases, about 70% present as superficial disease and this while rarely fatal, tends to recur, requiring long-term follow-up and repeat interventions. The standard of care, intravesical chemo- and immunotherapy, while effective, is associated with a considerable side-effect profile and approximately 30% of patients either fail to respond to treatment or suffer recurrent disease within 5 years. Muscle-invasive bladder cancer is life threatening, showing modest chemosensitivity, and usually requires radical cystectomy. Although bladder cancer is fairly well-genetically characterized, clinical trials with molecularly targeted agents have, in comparison to other solid tumors such as lung, breast and prostate, been few in number and largely unsuccessful, with no new agents being registered in the last 20 years. Hence, bladder cancer represents a considerable opportunity and challenge for molecularly targeted therapy. © 2009 Springer Science+Business Media, LLC.
    Original languageEnglish
    Pages (from-to)355-367
    Number of pages12
    JournalCancer and Metastasis Reviews
    Issue number3-4
    Publication statusPublished - 2009


    • Bladder cancer
    • Targeted therapies
    • Treatment


    Dive into the research topics of 'Emerging targeted therapies for bladder cancer: A disease waiting for a drug'. Together they form a unique fingerprint.

    Cite this